abiraterone

12/01/2020 - "After his diagnosis, the patient has become an outspoken advocate and fundraiser for prostate cancer awareness and wants to ensure that novel treatments with proven efficacy and tolerability, such as abiraterone, are available for all men in his condition. "
07/01/2021 - "Impressively, abiraterone in conjunction with ADT as a first-line treatment for castrate-sensitive prostate cancer also confers a significant overall survival benefit compared to ADT alone. "
04/01/2019 - "Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer."
01/01/2023 - "We did not find sufficient evidence of a difference in treatment effect from abiraterone on score change over time in prostate cancer subscale (interaction p = 0.4), trial outcome index (interaction p = 0.8), and FACT-P total score (interaction p = 0.6) depending on the receipt of prior LT. "
01/01/2022 - "The purpose of the study was to investigate explore the metabolites of the anti-prostate cancer drug Abiraterone by examining gut microbiota metabolism and hepatic metabolism in vitro. "

01/01/2022 - "To identify alternative treatment for abiraterone nonresponders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in tumor biopsies and patient-derived xenograft (PDX) tumors between abiraterone responders and nonresponders enrolled in PROMOTE trial. "
01/01/2023 - "In addition, combined treatment inhibited tumor growth in an in vivo abiraterone-resistant xenograft model, blocked stemness, migration, invasion, and colony formation ability of cancer cells. "
01/01/2023 - "Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types."
12/19/2022 - "A combination of QLD and abiraterone yielded a better tumor inhibition effect than QLD alone and abiraterone alone. "
09/01/2022 - "Moreover, we also found a reduction in AR activation in C4-2B cells (p = 0.017) confirming the "indirect" anti-tumor AR-dependent effect of abiraterone mediated by osteoblasts. "

01/01/2019 - "Our objective was to determine whether abiraterone increased the risk of development of visceral metastases at the time of progression compared with placebo in a randomized phase III trial. "
01/01/2022 - "Seven patients were excluded from the MFS analysis, including two with a history of abiraterone treatment and five with more than five metastases. "
01/01/2019 - "Abiraterone treatment was not associated with the development of visceral metastases in multivariable analysis (HR 0.89 [95% CI, 0.57-1.40]; P = .62). "
01/01/2019 - "Multivariable Cox regression analysis assessed for the independent association of abiraterone with the development of visceral metastases. "
01/01/2019 - "We hypothesized that the therapeutic pressure of abiraterone is resulting in more clinically aggressive disease at progression, characterized by increased visceral metastases. "

07/01/2012 - "Abiraterone provides a moderate improvement in disease progression and mortality in a patient population with limited treatment options. "
09/01/2022 - "Intriguingly, clinical data revealed that abiraterone also delayed disease progression in bone improving bone-related endpoints. "
01/01/2021 - "Patients with a CDK12 defect showed rapid disease progression after abiraterone treatment. "
01/01/2017 - "The median length of radiographic progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). "
03/01/2021 - "The results of this study suggest that a large clinical study of adaptive abiraterone therapy is warranted to validate the potential of this strategy to extend the time to disease progression and reduce costs of treatment of metastatic CRPC."

01/01/2022 - "mCRPC patients were enrolled at abiraterone start (February 2016-June 2017) and followed up for 3 years; clinical endpoints and PROs, including quality of life (QoL) and pain, were prospectively collected. "
05/01/2017 - "Patients with pain and poor PS are at higher risk of DDI with abiraterone. "
05/01/2017 - "In the univariate analysis, pain (p < 0.0001), hypo-albuminemia (p = 0.032), and higher ECOG performance status (PS) (p = 0.013) were significantly associated with a higher risk of DDI with abiraterone. "
01/01/2016 - "RaTot, ALP, initial ECOG status, initial pain score, and use of abiraterone were associated with OS (p ≤ 0.008), PFS (p ≤ 0.003), and BeFS (p ≤ 0.020). "
06/01/2015 - "After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. "